Dopamine Inhibits the Expression of Hepatitis B Virus Surface and E Antigens by Activating the JAK/STAT Pathway and Upregulating Interferon-stimulated Gene 15 Expression

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2024 May 23

PMID 38779516

Authors

Xiaoquan Liu

Xiuqing Pang

Zhiping Wan

Jinhua Zhao

Zhiliang Gao

Hong Deng

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Hepatitis B virus (HBV) infection is a major risk factor for cirrhosis and liver cancer, and its treatment continues to be difficult. We previously demonstrated that a dopamine analog inhibited the packaging of pregenomic RNA into capsids. The present study aimed to determine the effect of dopamine on the expressions of hepatitis B virus surface and e antigens (HBsAg and HBeAg, respectively) and to elucidate the underlying mechanism.

Methods: We used dopamine-treated HBV-infected HepG2.2.15 and NTCP-G2 cells to monitor HBsAg and HBeAg expression levels. We analyzed interferon-stimulated gene 15 (ISG15) expression in dopamine-treated cells. We knocked down ISG15 and then monitored HBsAg and HBeAg expression levels. We analyzed the expression of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway factors in dopamine-treated cells. We used dopamine hydrochloride-treated adeno-associated virus/HBV-infected mouse model to evaluate HBV DNA, HBsAg, and HBeAg expression. HBV virus was collected from HepAD38.7 cell culture medium.

Results: Dopamine inhibited HBsAg and HBeAg expression and upregulated ISG15 expression in HepG2.2.15 and HepG2-NTCP cell lines. ISG15 knockdown increased HBsAg and HBeAg expression in HepG2.2.15 cells. Dopamine-treated cells activated the JAK/STAT pathway, which upregulated ISG15 expression. In the adeno-associated virus-HBV murine infection model, dopamine downregulated HBsAg and HBeAg expression and activated the JAK-STAT/ISG15 axis.

Conclusions: Dopamine inhibits the expression of HBsAg and HBeAg by activating the JAK/STAT pathway and upregulating ISG15 expression.

References

Lin L, Guo J, Liu H, Jiang X . Rapid Detection of Hepatitis B Virus in Blood Samples Using a Combination of Polymerase Spiral Reaction With Nanoparticles Lateral-Flow Biosensor. Front Mol Biosci. 2021; 7:578892. PMC: 7818967. DOI: 10.3389/fmolb.2020.578892. View

Medina G, Azzinaro P, Ramirez-Medina E, Gutkoska J, Fang Y, Diaz-San Segundo F . Impairment of the DeISGylation Activity of Foot-and-Mouth Disease Virus Lpro Causes Attenuation and . J Virol. 2020; 94(13). PMC: 7307143. DOI: 10.1128/JVI.00341-20. View

Yan Y, Pan J, Chen Y, Xing W, Li Q, Wang D . Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. Cancer Commun (Lond). 2020; 40(12):694-710. PMC: 7743025. DOI: 10.1002/cac2.12103. View

Wei L, Ploss A . Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. 2020; 5(5):715-726. PMC: 7190442. DOI: 10.1038/s41564-020-0678-0. View

Radoshevich L, Impens F, Ribet D, Quereda J, Tham T, Nahori M . ISG15 counteracts Listeria monocytogenes infection. Elife. 2015; 4. PMC: 4530601. DOI: 10.7554/eLife.06848. View

de Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P . Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine. 2020; 55:102779. PMC: 7225620. DOI: 10.1016/j.ebiom.2020.102779. View

McFadden W, Sarafianos S . Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure. Glob Health Med. 2023; 5(4):199-207. PMC: 10461335. DOI: 10.35772/ghm.2023.01065. View

Liu H, Hong X, Xi J, Menne S, Hu J, Wang J . Cryo-EM structures of human hepatitis B and woodchuck hepatitis virus small spherical subviral particles. Sci Adv. 2022; 8(31):eabo4184. PMC: 9355357. DOI: 10.1126/sciadv.abo4184. View

Lo H, Hui K, Lai H, He X, Khan K, Kaur S . Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Cent Sci. 2021; 7(5):792-802. PMC: 8056950. DOI: 10.1021/acscentsci.0c01186. View

10.

Liu X, Ohsaki E, Ueda K . Establishment of a system for finding inhibitors of ε RNA binding with the HBV polymerase. Genes Cells. 2020; 25(8):523-537. PMC: 7496097. DOI: 10.1111/gtc.12778. View

11.

Pacella I, Spinelli F, Severa M, Timperi E, Tucci G, Zagaglioni M . ISG15 protects human Tregs from interferon alpha-induced contraction in a cell-intrinsic fashion. Clin Transl Immunology. 2020; 9(12):e1221. PMC: 7758615. DOI: 10.1002/cti2.1221. View

12.

Yang X, Cai W, Sun X, Bi Y, Zeng C, Zhao X . Defined host factors support HBV infection in non-hepatic 293T cells. J Cell Mol Med. 2020; 24(4):2507-2518. PMC: 7028854. DOI: 10.1111/jcmm.14944. View

13.

Cruz M, Parks G . La Crosse Virus Infection of Human Keratinocytes Leads to Interferon-Dependent Apoptosis of Bystander Non-Infected Cells In Vitro. Viruses. 2020; 12(3). PMC: 7150866. DOI: 10.3390/v12030253. View

14.

Abdelwahed A, Heineman B, Wu G . Novel Approaches to Inhibition of HBsAg Expression from cccDNA and Chromosomal Integrants: A Review. J Clin Transl Hepatol. 2024; 11(7):1485-1497. PMC: 10752814. DOI: 10.14218/JCTH.2023.00067. View

15.

Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y . Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virol Sin. 2022; 37(3):390-397. PMC: 9243604. DOI: 10.1016/j.virs.2022.03.001. View

16.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X . Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343(6176):1221-8. PMC: 6309542. DOI: 10.1126/science.1243462. View

17.

Durantel D, Zoulim F . New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016; 64(1 Suppl):S117-S131. DOI: 10.1016/j.jhep.2016.02.016. View

18.

Alawad A, Auh S, Suarez D, Ghany M . Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. Clin Gastroenterol Hepatol. 2019; 18(3):700-709.e3. PMC: 6962568. DOI: 10.1016/j.cgh.2019.07.018. View

19.

Chen B, Chen Y, Li J, Wang C, Song W, Wen Y . A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. mBio. 2022; 13(4):e0161222. PMC: 9426588. DOI: 10.1128/mbio.01612-22. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View